Company profile
MedImmune LLC
Privately held: no public share price
Assets
(5 total)
5Total Assets
3Approved
2Phase 3 / Filed
0Phase 1–2 / Early
5Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | Type I interferon receptor · Type I interferon receptor subunit 1 (IFNAR1)Monoclonal antibody | Systemic Lupus Erythematosus | |
Benralizumab(Fasenra) | Approved | IL-5 receptor alpha · IL-5 receptor alpha (IL-5Rα / CD125); Fc region additionally engages FcγRIIIa on NK cells (ADCC) · IL-5 receptor alpha (IL5RA) on eosinophils/basophilsMonoclonal antibody | Chronic Obstructive Pulmonary DiseaseAsthma |
| Approved | CTLA-4Monoclonal antibody | Non-Small Cell Lung Cancer | |
| Phase 3 | NKG2AMonoclonal antibody | Non-Small Cell Lung CancerHead and Neck Squamous Cell Carcinoma | |
| Phase 3 | CD73Monoclonal antibody | Non-Small Cell Lung Cancer |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.